Abstract:ID 92395 Poster Board 511 Opioid Use Disorder (OUD) is a chronic, relapsing disease that, despite our best research efforts, has become a worsening public health crisis. Currently, the medications to treat OUD belong to the opioid class of drugs and, therefore, continue to interact directly with opioid receptors. While these medications are safe and effective for the cessation of opioids with higher abuse potentials, there is still a need for effective non-opioid receptor-targeting therapeutics. Exploring novel non-opioid targets is necessary to overcome this barrier. One such non-opioid target we are currently investigating is the calcitonin gene-related peptide (CGRP) system, particularly CGRP-expressing neurons in the parabrachial nucleus (CGRP PBN ). These neurons have been well studied in itch and pain and are known to project to brain regions implicated in opioid reward and withdrawal. Previous studies in our lab have found that CGRP PBN activity decreases during opioid taking and increases during opioid withdrawal. To further characterize the behavioral role of CGRP PBN neurons in opioid withdrawal, Calca-Cre transgenic mice received viral injections into the PBN containing an inhibitory DREADD (hm4Di), and two weeks later, mice were implanted with 2x25 mg morphine pellets. After five days, morphine withdrawal was induced by removing the pellets. Mice were administered either clozapine-N-oxide (CNO) (3 mg/kg, I.P.) or vehicle (saline, I.P.) 5.5 hours post pellet removal, and behavior was recorded at 6 and 24 hours post pellet removal. Two experimenters scored videos for jumping and wet dog shakes. Those mice injected with CNO showed fewer wet-dog shakes at the 6-hour time than vehicle-injected controls. We next sought to characterize the behavioral role of CGRP PBN neurons in opioid taking. In this experiment, morphine intravenous self-administration (IVSA) was used. Calca-Cre transgenic mice received viral injections into the PBN containing either an inhibitory DREADD (hm4Di) or a control mCherry vector and, two weeks later, were implanted with jugular catheters. Subsequently, operant responding for intravenous morphine was established. After 12 daily sessions, mice were administered CNO (3 mg/kg, I.P.) or vehicle (saline, I.P.) and allowed to respond for morphine. CGRP PBN inhibition reduced morphine intake in hm4Di-injected animals, while those with a control virus maintained their previous levels of morphine intake. Decreases in morphine intake were maintained 24 hours after CNO administration but returned to previous baseline levels at 48 hours. These results suggest that CGRP PBN neurons play a role in the behavioral consequences of both opioid reinforcement and withdrawal. CGRP receptor inhibitors are FDA-approved for the treatment of migraine and exist in both short and long-lasting formulations. By leveraging these available medications for the off-label purpose of treating OUD, we may be able to determine the translational potential of these preclinical findings and, therefore, expand our therapeutic arsenal for long-term maintenance of opioid abstinence and relapse.

Parvalbumin Interneurons of Central Amygdala Regulate the Negative Affective States and the Expression of Corticotrophin-Releasing Hormone During Morphine Withdrawal.

Corticotrophin-releasing hormone neurons in the central amygdala mediate morphine withdrawal-induced negative emotions

CRHCeA→VTA inputs inhibit the positive ensembles to induce negative effect of opiate withdrawal

[Changs of Kappa Opioid Receptor Expression in Central Amygdaloid Nuclei During the Process of Chronic Morphine-Induced Conditioned Place Aversion in Rats].

Inputs from Paraventricular Nucleus of Thalamus and Locus Coeruleus Contribute to the Activation of Central Nucleus of Amygdala During Context-Induced Retrieval of Morphine Withdrawal Memory.

The Basolateral Amygdala to Ventral Hippocampus Circuit Controls Anxiety-like Behaviors Induced by Morphine Withdrawal

Contributions of the GABAergic system of the prelimbic cortex and basolateral amygdala to morphine withdrawal-induced contextual fear

GluA1 in Central Amygdala Increases Pain but Inhibits Opioid Withdrawal-Induced Aversion

VTA μ-opioidergic neurons facilitate low sociability in protracted opioid withdrawal

Changes of Protein Expression Profiles in the Amygdala During the Process of Morphine-Induced Conditioned Place Preference in Rats

Persistent Pain Facilitates Response to Morphine Reward by Downregulation of Central Amygdala GABAergic Function

Striatal μ-opioid receptor activation triggers direct-pathway GABAergic plasticity and induces negative affect

Persistent Pain Maintains Morphine-Seeking Behavior after Morphine Withdrawal Through Reduced MeCP2 Repression of Glua1 in Rat Central Amygdala

Synaptic properties and postsynaptic opioid effects in rat central amygdala neurons.

Formation of chronic morphine withdrawal memories requires C1QL3-mediated regulation of PSD95 in the mouse basolateral amygdala

Opioid Withdrawal Abruptly Disrupts Amygdala Circuit Function by Reducing Peptide Actions

Ionotropic Glutamatergic Neurotransmission in the Ventral Tegmental Area Modulates ΔFosB Expression in the Nucleus Accumbens and Abstinence Syndrome in Morphine Withdrawal Rats

Amygdalar κ-opioid receptor-dependent upregulating glutamate transporter 1 mediates depressive-like behaviors of opioid abstinence

Inhibition of Parabrachial CGRP Neurons Reduces Morphine Reinforcement and Withdrawal

Upregulation of Nerve Growth Factor in Central Amygdala Increases Sensitivity to Opioid Reward

Opioid Signal Transduction Regulates The Dendritic Morphology Of Somatostatin And Parvalbumin Interneurons In The Medial Prefrontal Cortex